Business
Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor.
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, ON, Oct. 11 /CNW/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt:\nWKN 918864) announced today the addition of Kenneth D. Hatch, M.D., as a new\nmedical advisor to the Company. Dr. Hatch will provide guidance to Helix on\nits clinical-stage compound, Topical Interferon Alpha-2b, for the treatment of\nconditions caused by HPV. Dr. Hatch is a professor of obstetrics and\ngynecology at the University of Arizona.\n\n\n"Dr. Hatch complements our medical advisory team and brings additional\nstrength to Helix' expertise in the field of gynecology and pre-invasive\ndiseases of the cervix", said John Docherty, vice president, corporate\ndevelopment at Helix. "We are very pleased to establish this relationship with\nDr. Hatch, and expect that he will be an invaluable asset to the Company as we\ncontinue to move forward with the preparations for our planned IND/CTA filings\nfor Topical Interferon Alpha-2b".\n\n\nPreviously, Dr. Hatch was president of the American Society of Colposcopy\nand Cervical Pathology. Dr. Hatch has also presided as secretary-treasurer of\nthe International Federation of Colposcopy and Cervical Pathology, and as\npresident of the Society of Gynecologic Oncologists.\n\n\nAbout Helix BioPharma Corp.\n\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The Company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha-2b, for the treatment of conditions caused by HPV, and its\nnovel L-DOS47 new drug product candidate for the treatment of lung\nadenocarcinoma. Helix is listed on the Toronto Stock Exchange under the ticker\nsymbol "HBP".\n\n\nThis News Release contains certain forward-looking statements and\ninformation regarding Helix's product development initiatives, Topical\nInterferon Alpha-2b and L-DOS47. Forward-looking statements and information\ncan be identified by the use of forward-looking terminology such as "expect",\n"planned", "developing", and "initiatives". Helix's actual results could\ndiffer materially from those anticipated in these forward-looking statements\nand information as a result of numerous factors, including w...